Rex Bionics PLC Director Dealing (0750H)
May 14 2014 - 4:20AM
UK Regulatory
TIDMRXB
RNS Number : 0750H
Rex Bionics PLC
14 May 2014
14 May 2014
Rex Bionics plc
("Rex Bionics" or the "Company")
Director Dealing
Rex Bionics plc (AIM: RXB), the developer and manufacturer of
REX products: hands-free robotic exoskeletons for use by wheelchair
users, announces that it has received notification yesterday that
Victoria Provis, a non-executive director of the Company, purchased
5,000 ordinary shares of GBP1.00 each ("Ordinary Shares") in the
Company yesterday, at a price of 176.95 pence per share.
Following this purchase, Victoria Provis has an interest in
5,000 Ordinary Shares representing 0.03% of the entire issued share
capital of the Company.
For further information please contact:
Rex Bionics Plc
Jeremy Curnock Cook, Chief Executive Officer
Peter Worrall, Chief Financial Officer
+44 (0)142 864 5416
Oriel Securities Limited (NOMAD and Broker)
Juliet Thompson/Jonathan Senior
+44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson / Jessica Hodgson / Lindsey
Neville
rexbionics@consilium-comms.com
+44 (0) 203 709 5700
About Rex Bionics
Rex Bionics (AIM: RXB) is an AIM-listed developer and
manufacturer of REX products, hands-free robotic exoskeletons for
use by people with mobility impairments. Founded in Auckland, New
Zealand by two robotics engineers with first-hand experience of
wheelchair users and their needs, Rex Bionics focuses on producing
products designed to enable wheelchair users to stand and walk
autonomously without the need for crutches or supports and is the
only company to mass produce hands-free walking devices for
wheelchair users. Rex Bionics' marketed products: REX Rehab and REX
Personal, can be used by people with complete spinal cord injury,
but also by a much broader potential customer base, including
people with multiple sclerosis and muscular dystrophy. In May 2014,
Rex Bionics joined AIM with a fundraising of GBP10 million (gross)
to scale up production, distribution and marketing internationally,
in order to support growing demand for both REX products as well as
developing the next generation of REX devices, REX 3.
For more information please visit, www.rexbionics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDNUSAWRSBAVARR
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Aug 2023 to Aug 2024